COVID-19 vaccine blood clot feared: Under 40s will be offered an AstraZeneca vaccine alternative as advice changes UK news

Everyone under 40 will be offered an alternative to the Oxford-AstraZeneca coronavirus vaccine as a precaution.

The change of opinion of the Joint Committee on Vaccination and Immunization marks an extension to existing guidance when these under the age of 30 had the choice between COVID-19[female[feminine jab on blood clotting problems.

Live coronavirus updates from UK and around the world

The Medicines and Health Products Regulatory Agency (MHRA) had said that the balance of risks to the AstraZeneca vaccine against coronavirus is very favorable for the elderly but “more finely balanced” for the younger groups, who do not tend to suffer from serious illnesses with COVID.

The latest data from the MHRA shows that there were 242 blood clots associated with low platelets in more than 28 million people who received the AstraZeneca vaccine through April 28.

The overall incidence of blood clots with low platelets after a first dose is estimated to be 10.5 per million doses, and approximately one in a million for a second dose.

For people aged 40 to 49, the incidence is 10.1 per million doses and 17.4 per million for those aged 30 to 39.

Overall, the death rate per million doses is 2.1, but it is 4.5 for those aged 30 to 39.

The JCVI said another vaccine should only be given if it does not cause a major delay in vaccination.

Although COVID cases are currently low, modeling suggests that a significant delay in vaccine deployment would make a third wave more likely.

The JCVU added that AstraZeneca jab is the only one of the three vaccines allowed to be dispensed at refrigerator temperature, which may mean in some circumstances that this is the only practical dose to offer.

People who have already received a dose of AstraZeneca vaccine without relevant side effects will also be offered the second time.

Professor Wei Shen Lim, COVID-19 …